Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate

International Journal of Cancer

Volumn 73, Issue 6, 1997, Pages 865-870

  Olson, Timothy A ^a   Mohanraj, D ^a   Roy, Sabita ^a   Ramakrishnan, S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; ENDOTHELIAL CELL GROWTH FACTOR; IMMUNOTOXIN; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; ARTICLE; BLEEDING; CANCER TRANSPLANTATION; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; KIDNEY; LIVER; LUNG; MOUSE; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; OVARY TUMOR; PATHOLOGY; VASCULARIZATION;

ANIMALS; DIPHTHERIA TOXIN; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEMORRHAGE; HUMANS; IMMUNOTOXINS; KIDNEY; LIVER; LUNG; LYMPHOKINES; MICE; MICE, NUDE; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031564123     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971210)73:6<865::AID-IJC17>3.0.CO;2-3     Document Type: Article

References (43)

1. AUERBACH, W. and AUERBACH, R., Angiogenesis inhibition: a review. Pharmacol. Ther., 63, 265-311 (1994).
2. BEITZ, J.G., DAVOL-LEWIS, P., CLARK, J.W., KATO, J., MEDINA, M., FRACKELTON, A.R., LAPPI, D.A., BAIRD, A., and CALABRESI, P., Antitumor activity of basic FGF-saporin mitotoxin in vitro and in vivo. Cancer Res., 52, 227-230 (1992).
3. BROWN, L.F., BERSE, B., JACKMAN, R.W., TONGNAZZI, K., MANSEAU, E.J., SENGER, D.R. and DVORAK, H.F., Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53, 4727-4735 (1993).
4. BURROWS, F.J., DERBYSHIRE, E.J., TAZZARI, P.L., AMLOT, P., GAZDAR, A.F., KING, S.W., LETARTE, M., VITETTA, E.S. and THORPE, P.E., Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res., 1, 1623-1634 (1995).
5. BURROWS, F.J. and THORPE, P.E., Eradication of large solid tumors in mice with an immunotoxin directed against the tumor vasculature. Proc. nat. Acad. Sci. (Wash.), 90, 8996-9000 (1993).
6. BURROWS, F.J. and THORPE, P.E., Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol. Ther., 64, 155-174 (1994).
7. CAO, Y. CHEN, H., ZHOU, L., CHIANG, M.K., ANAND-APTE, B., WETHERBEE, J.A., WANG, Y., FANG, F., FLANAGAN, J.G. and TSANG, M.L., Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J. biol. Chem., 271, 3154-3162 (1996).
8. DE VRIES, C., ESCOBEDO, J.A., UENO, H., HOUCK, K.A., FERRARA, N. and WILLIAMS, L.T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991 (1992).
9. DENEKAMP, J., Endothelial cell proliferation as a novel approach to targeting tumour therapy. Brit. J. Cancer, 45, 136-139 (1982).
10. DI SALVO, J., BAYNE, M.L., CONN, G., KWOK, P.W., TRIVEDI, P.G., SODERMAN, D.D., PALISI, T.M., SULLIVAN, K.A. and THOMAS, K.A., Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer. J. biol. Chem., 270, 7717-7723 (1995).
11. DVORAK, H.F., DETMAR, M., CLAFFEY, K.P., NAGY, J.A., VAN DE WATER, L. and SENGER, D.R., Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int. Arch. Allerg. Immunol., 107, 233-235 (1995).
12. FERRARA, N., The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat., 36, 127-137 (1995).
13. FERRARA, N. and DAVIS-SMYTH, T., The biology of vascular endothelial growth factor. Endocrinol. Rev., 18, 4-25 (1997).
14. FOLKMAN, J., What is the evidence that tumors are angiogenesis dependent? J. nat. Cancer Inst., 82, 4-6 (1990).
15. FULCHER, S., LUI, G., HOUSTON, L.L., RAMAKRISHNAN, S., BURRIS, T., POLANSKY, J. and ALVARADO, J., Use of immunotoxins to inhibit proliferating human corneal endothelium. Invest. Ophthalmol. vis. Sci., 29, 755-759 (1988).
16. GAWLAK, S.L., PASTAN, I. and SIEGALL, C.B., Basic fibroblast growth factor. Pseudomonas exotoxin chimeric proteins: comparison with acidic fibroblast growth factor-Pseudomonas exotoxin. Bioconj. Chem., 4, 483-489 (1993).
17. HANAHAN, D. and FOLKMAN, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364 (1996).
18. HUANG, X., MOLEMA, G., KING, S., WATKINS, L., EDGINOTON, T.S. and THORPE, P.E., Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275, 547-550 (1997).
19. JAIN, R.K., Therapeutic implications of tumor physiology. Curr. Opin. Oncol., 3, 1105-1108 (1991).
20. JELTSCH, M., KAIPAINEN, A., JOUKOV, V., MENG, X., LASKO, M., RAUVALA, H., SWARTZ, M., FUKUMURA, D., JAIN, R.K. and ALITALO, K., Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 276, 1423-1425 (1997).
21. JOUKOV, V., PAJUSOLA, K., KAIPAINEN, A., CHILOV, D., LATHINEN, I., KUKK, E., SAKESELA, O., KALKKINEN, N. and ALITALO, K., A novel vascular endothelial growth factor, VEGF-C, is ligand for the FLT4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 15, 290-298 (1996).
22. KAIPAINEN, A., KORHONEN, K., MUSTONEN, V., VAN HINSBERGH, V.W., FANG, D., DUMONT, D., BREITMAN, M. and ALITALO, K., Expression of FLT4 receptor tyrosine kinase becomes restricted to lymphatic endothelium during development. Proc. nat. Acad. Sci. (Wash.), 92, 3566-3570 (1995).
23. KIM, K.J., LI, B., WINER, J., ARMANINI, M., GILLET, N., PHILLIPS, H. and FERRARA, N., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362, 841-844 (1993).
24. KOLCH, W., MARTINY-BARON, G., KIESER, A. and MARME, D., Regulation of the expression of the VEGF/VPF and its receptors: role in tumor angiogenesis. Breast Cancer Res. Treat., 36, 139-155 (1995).
25. LAPPI, D.A., Tumor targeting through fibroblast growth factor receptors. Semin. Cancer Biol., 6, 279-288 (1995).
26. LAPPI, D.A., MAHER, P.A., MARTINEAU, D. and BAIRD, A., The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J. Cell Physiol., 147, 17-26 (1991).
27. LEE, J., GRAY, A., YUAN, J., LUOH, S-M., AVRAHAM, M. and WOOD, W.I., Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. nat. Acad. Sci. (Wash.), 93, 1988-1992 (1996).
28. MAGLIONE, D., GUERRIERO, V., VIGLIETTO, G., DELLI-BOVI, P. and PERSICO, M.G., Isolation of a human placenta cDNA coding for protein related to the vascular permiability factor. Proc. nat. Acad Sci. (Wash.), 88, 9267-9271 (1991).
29. MAISONPIERRE, P.C. and 13 OTHERS, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60 (1997).
30. MILLAUER, B., SHAWVER, L.K., PLATE, K.H., RISAU, W. and ULLRICH, A., Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature (Lond.), 367, 576-579 (1994).
31. MILLAUER, B., WIZIGMANN-VOSS, S., SCHNURCH, H., MARTINEZ, R., MOLLER, N.P., RISAU, W. and ULRICH, A., High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835-846 (1993).
32. MUSTONEN, T. and ALITALO, K., Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol., 129, 895-898 (1995).
33. OLOFSSON, B., PAJUSOLA, K., KAIPAINEN, A., VON EULER, G., JOUKOV, V., SAKSELA, O., ORPANA, A., PETTERSSON, R.F., ALITALO, K. and ERIKSSON, U., Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. nat. Acad. Sci. (Wash.), 93, 2576-2581 (1996).
34. OLSON, T.A., MOHANRAJ, D., CARSON, L.F. and RAMAKRISHNAN, S., Vascular permeability factor expression in normal and neoplastic human ovaries. Cancer Res., 54, 276-280 (1994).
35. OLSON, T.A., MOHANRAJ, D. and RAMAKRISHNAN, S., In vivo neutralization of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int. J. Oncol. 8, 505-511 (1996).
36. PLATE, K.H., BREIER, G., MILLAUER, B., ULLRICH, A. and RISAU, W., Up-regulalion of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 53, 5822-5827 (1993).
37. QUINN, T., PETERS, K.G., DE VRIES, C., FERRARA, N. and WILLIAMS, L.T., Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. nat. Acad. Sci. (Wash.), 90, 7533-7537 (1993).
38. RAMAKRISHNAN, S., OLSON, T.A., BAUCH, V.L. and MOHANRAJ, D., Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56, 1324-1330 (1996).
39. SHIBUYA, M., YAMAGUCHI, S., YAMANE, A., IKADA, T., TOJO, T., MATSUSHIME, H. and SATO, M., Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogens, 8, 519-527 (1990).
40. SIEGALL, C.B., Targeted toxins as anticancer agents. Cancer, 74, 1006-1012 (1994).
41. SIEGALL, C.B., GAWLAK, S.L., CHACE, D.F., MERWIN, J.R. and PASTAN, I., In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins. Bioconj. Chem., 5, 77-83 (1994).
42. SURI, C., JONES, P.F., PATAN, S., BARTUNKOVA, S., MAISONPIERRE, P.C., DAVIS, S., SATO, T.N. and YANCOPOULOS, G.D., Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87, 1171-1180 (1996).
43. TERMAN, B.I., CARRION, M.E., KOVACS, E., RASMUSSEN, B.A., EDDY, R.L. and SHOWS, T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 6, 519-524 (1991).